Skip to main content
Uncategorized

Oryzon begins clinical diagnostics in humans

By 12 de July de 2010November 18th, 2020No Comments
< Back to news
 12.07.2010

Oryzon begins clinical diagnostics in humans

Catalan biotechnology company Oryzon has just received authorization from the Government of Catalonia to carry out clinical diagnostics in humans. This certification will allow the company to commercialize products they are developing in oncology and neurodegenerative diseases, two key areas of the company's activity.

“It is not uncommon for a laboratory to carry out clinical diagnostics in humans. However, it is less common for a company from the biotech sector to receive this type of accreditation, allowing them to market products they have created,” explained Carlos Buesa, CEO of Oryzon.

Oryzon has discovered biomarkers that are potential therapeutic targets. These targets have new action mechanisms that allow for improved management of neurodegenerative and oncological diseases.Two of their most advanced products, which are currently in the development stage, are a biomarker to diagnose uterine cancer and a treatment for Huntington’s neurological disease.

They are also participating in the CENIT ONCNOSIS project, together with Siemens Medical, the Catalan Institute of Oncology, the Vall d’Hebron University Hospital, and twenty universities, to identify lung, ovarian, skin and colon cancer. The company’s own oncology projects are expected to have a number of totally new molecules with high therapeutic value, meaning they shut down key genes in the cancer process, in the clinical phases by 2012, which will allow them to develop a new generation of drugs against this disease.

Created in 2000, Oryzon has become one of the fastest growing companies in the national biotech sector in less than 10 years.

For more information